Innovent Biologics Secures $80 Million in Funding for Cutting-Edge Medicines

Innovent Biologics, a pioneering leader in innovative biologic medicines since its establishment in 2011, is excited to announce that it has successfully raised $80 million in its latest funding round. This significant capital infusion comes as Innovent continues its commitment to revolutionizing treatments for major diseases, particularly cancer, by expanding its robust pipeline of therapeutic assets. Having been publicly listed on the Hong Kong Stock Exchange since October 31, 2018, Innovent has already achieved remarkable milestones with four market-approved products, including the notable TYVYT® (sintilimab injection), which marked a milestone as the first PD-1 inhibitor included in China’s National Reimbursement Drug List. The funds raised will be strategically utilized to accelerate clinical development across its pipeline of 23 valuable assets, including five currently in advanced Phase III trials. Moreover, the financing will support Innovent's ongoing efforts to enhance its fully-integrated, multi-functional platform that encompasses research and development, manufacturing, clinical trials, and commercialization. This funding marks a vital step forward in Innovent's mission to make high-quality and innovative medicines accessible to patients in need while reinforcing its status as a key player in the biopharmaceutical landscape. With state-of-the-art biopharma production facilities compliant with stringent global standards, Innovent is poised for continued growth and collaboration with industry leaders like Eli Lilly and Hanmi. As Innovent propels forward, it remains dedicated to transforming the future of medicine and improving patient outcomes globally.